newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

  • AEON Biopharma, Inc. (NYSE: AEON) will host one-on-one investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026.
  • The company is advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) to achieve full-label U.S. market entry for therapeutic use.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, presenting a major opportunity for biosimilar entry.
  • ABP-450 is the same botulinum toxin complex approved for cosmetic indications by Evolus, Inc. under the name Jeuveau ®.
  • ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the U.S. FDA, Health Canada, and the European Medicines Agency.
  • AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and other international territories.